After the adoption of CFTR modulators, a significantly higher expenditure was observed in Europe: a recent study reviewed a database of PWCF and showed that only the four percent of PWCF who were on CFTR modulators caused an increase of 27.5% in CF pharmaceutical spending (Chevreul et al., 2016). This evidence concerns the gene CFTR and cystic fibrosis.